A Study to Investigate Interleukin-6 (IL-6) and IL-6/Soluble IL-6 Receptor (sIL-6R) Complex Levels in Subjects With Active Inflammatory Bowel Disease
January 13, 2017 updated by: Ferring Pharmaceuticals
The purpose of this study is to measure IL-6 and IL-6/sIL-6R complex levels in subjects with active moderate to severe ulcerative colitis or Crohn's disease.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
33
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Men and women seeking medical support due to present, active moderate to severe ulcerative colitis or Crohn's disease (newly diagnosed or during disease relapse).
Description
Inclusion Criteria:
- Subjects diagnosed with active moderate to severe ulcerative colitis (*partial Mayo ≥ 5) or Crohn's disease (Harvey & Bradshaw ≥ 8) *partial Mayo: 9-point scale that excludes the endoscopic components of the Mayo score
Exclusion Criteria:
- Presence of another inflammatory disease, except for mild cutaneous psoriasis
- Concomitant gastrointestinal infection or otherwise serious infection including Crohn's disease infectious complication
- Treatment with Infliximab, Adalimumab, Certolizumab Pegol or other immune-modulating biologics within 8 weeks prior to the visit
- Having a known or suspected gastrointestinal or otherwise serious infection within 8 weeks prior to the visit
- Concomitant diagnosed or suspected malignant disease
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Exploratory: Levels of IL-6/sIL-6R Complex
Time Frame: At Day 1
|
Blood sample was taken for analysis of levels of IL-6/sIL6-R complex.
|
At Day 1
|
|
Exploratory: Levels of IL-6
Time Frame: At Day 1
|
Blood sample was taken for analysis of levels of IL-6.
|
At Day 1
|
|
Exploratory: Levels of C-reactive Protein (CRP)
Time Frame: At Day 1
|
Blood sample was taken for analysis of levels of CRP.
|
At Day 1
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2014
Primary Completion (Actual)
August 1, 2015
Study Completion (Actual)
August 1, 2015
Study Registration Dates
First Submitted
May 18, 2016
First Submitted That Met QC Criteria
June 2, 2016
First Posted (Estimate)
June 3, 2016
Study Record Updates
Last Update Posted (Actual)
March 6, 2017
Last Update Submitted That Met QC Criteria
January 13, 2017
Last Verified
January 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 07031-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.